Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer - Alexandros Papachristofilou, Madeleine M. Hipp, Ute Klinkhardt, Martin Früh, Martin Sebastian, Christian Weiss, Miklos Pless, Richard Cathomas, Wolfgang Hilbe, Georg Pall, Thomas Wehler, Jürgen Alt, Helge Bischoff, Michael Geißler, Frank Griesinger - Dissemin

Language
Login

Published in

BMJ Publishing Group, Journal for ImmunoTherapy of Cancer, 1(7), 2019

DOI: 10.1186/s40425-019-0520-5

Links

ORCID
BMJ Publishing Group | PDF

Tools

Export citation

Search in Google Scholar

Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer

Journal article published in 2019 by Alexandros Papachristofilou, Madeleine M. Hipp, Ute Klinkhardt, Martin Früh, Martin Sebastian, Christian Weiss, Miklos Pless, Richard Cathomas, Wolfgang Hilbe, Georg Pall, Thomas Wehler, Jürgen Alt, Helge Bischoff, Michael Geißler, Frank Griesinger and other authors.

This paper is made freely available by the publisher.

This paper is made freely available by the publisher.

Full text: Download

Green circle

Preprint: archiving allowed

Upload

Green circle

Postprint: archiving allowed

Upload

Green circle

Published version: archiving allowed

Upload

Policy details

Data provided by

SHERPA/RoMEO